Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

publishing date : 2021 - 08 - 18    symbols : LLY    save search

Global Hot Tobacco Markets Report 2021-2025 & 2030: HNB Devices, Direct/Indirect Heating, Infused/Hybrid Devices, Consumables, Sticks, Capsules & Cartridges
Published: 2021-08-18 (Crawled : 20:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M twitter stocktwits trandingview |
Health Technology
| | O: -0.88% H: 2.14% C: 1.6%
MO 4 | $41.3 0.49% 0.29% 15M twitter stocktwits trandingview |
Consumer Non-Durables
| | O: -0.83% H: 1.02% C: 0.88%

device
US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction
Published: 2021-08-18 (Crawled : 18:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M twitter stocktwits trandingview |
Health Technology
| | O: -0.26% H: 1.01% C: -1.28%

fda heart fda approval
EQRx Appoints Richard Buckley as Chief Corporate Affairs Officer
Published: 2021-08-18 (Crawled : 12:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M twitter stocktwits trandingview |
Health Technology
| | O: -0.26% H: 1.01% C: -1.28%


Home-Use Insulin Delivery Devices Market to Hit $19,087.6 Million Revenue by 2030 says P&S Intelligence
Published: 2021-08-18 (Crawled : 08:00) - prnewswire.com
NVO | $122.75 -1.43% 0.0% 2.8M twitter stocktwits trandingview |
Health Technology
| | O: 0.04% H: 0.72% C: -0.91%
MDT | $79.19 0.14% 0.0% 6.1M twitter stocktwits trandingview |
Health Technology
| | O: 0.03% H: 0.28% C: -1.12%
LLY | $745.95 -0.64% -0.1% 1.7M twitter stocktwits trandingview |
Health Technology
| | O: -0.26% H: 1.01% C: -1.28%
BDX | $233.15 0.41% 0.15% 890K twitter stocktwits trandingview |
Health Technology
| | O: 0.07% H: 0.3% C: -2.11%
SNY | News | $45.395 -1.55% -1.58% 4.4M twitter stocktwits trandingview |
Health Technology
| | O: 0.17% H: 1.16% C: -0.04%
PODD | $164.71 -0.93% -0.94% 590K twitter stocktwits trandingview |
Health Technology
| | O: 0.21% H: 0.12% C: -2.14%

insulin device liver
Significant Weight Loss and Multiple Metabolic Benefits: Phase 1b Study Results of IBI362 in Chinese Participants with Overweight or Obesity Published in EClinicalMedicine by the Lancet
Published: 2021-08-18 (Crawled : 00:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M twitter stocktwits trandingview |
Health Technology
| | O: -0.26% H: 1.01% C: -1.28%
INCY | $52.82 0.19% 0.19% 1.8M twitter stocktwits trandingview |
Health Technology
| | O: -0.11% H: 0.15% C: -1.38%

weight loss chinese obesity phase 1 results metabolic phase 1b lancet phase 2b
Gainers vs Losers
64% 36%

Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M twitter stocktwits trandingview |
Finance

ZCMD | $2.86 108.76% 52.1% 2.3M twitter stocktwits trandingview |
Commercial Services

INVO | $1.555 104.6% 51.13% 5M twitter stocktwits trandingview |
Health Technology

ISPC | $0.437 105.16% 49.53% 37M twitter stocktwits trandingview |
Professional, Scientific, and T...

WLGS | News | $0.92 84.0% 45.65% 1.6M twitter stocktwits trandingview |

OST | $0.499 21.38% 45.26% 1.9M twitter stocktwits trandingview |

XPON | News | $3.1 60.62% 37.74% 17M twitter stocktwits trandingview |

TIRX | $0.7 44.39% 30.74% 58M twitter stocktwits trandingview |

BNTC | News | $6.92 44.17% 30.64% 3.5M twitter stocktwits trandingview |
Health Technology

GGE | $0.035 19.86% 29.3% 64M twitter stocktwits trandingview |


Your saved searches
Save your searches and get alerts when important news are released.